Blocking TLR7- and TLR9-mediated IFN-α Production by Plasmacytoid Dendritic Cells Does Not Diminish Immune Activation in Early SIV Infection by Kader, M et al.
Blocking TLR7- and TLR9-mediated IFN-a Production by
Plasmacytoid Dendritic Cells Does Not Diminish Immune
Activation in Early SIV Infection
Muhamuda Kader1,2, Amanda P. Smith1,2, Cristiana Guiducci3, Elizabeth R. Wonderlich1,2,
Daniel Normolle4, Simon C. Watkins5, Franck J. Barrat3¤, Simon M. Barratt-Boyes1,2,6*
1Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 2Department of Infectious Diseases and Microbiology,
University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 3Dynavax Technologies Corporation, Berkeley, California, United States of America,
4Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 5Department of Cell Biology and Physiology, University of
Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 6Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
Abstract
Persistent production of type I interferon (IFN) by activated plasmacytoid dendritic cells (pDC) is a leading model to explain
chronic immune activation in human immunodeficiency virus (HIV) infection but direct evidence for this is lacking. We used
a dual antagonist of Toll-like receptor (TLR) 7 and TLR9 to selectively inhibit responses of pDC but not other mononuclear
phagocytes to viral RNA prior to and for 8 weeks following pathogenic simian immunodeficiency virus (SIV) infection of
rhesus macaques. We show that pDC are major but not exclusive producers of IFN-a that rapidly become unresponsive to
virus stimulation following SIV infection, whereas myeloid DC gain the capacity to produce IFN-a, albeit at low levels. pDC
mediate a marked but transient IFN-a response in lymph nodes during the acute phase that is blocked by administration of
TLR7 and TLR9 antagonist without impacting pDC recruitment. TLR7 and TLR9 blockade did not impact virus load or the
acute IFN-a response in plasma and had minimal effect on expression of IFN-stimulated genes in both blood and lymph
node. TLR7 and TLR9 blockade did not prevent activation of memory CD4+ and CD8+ T cells in blood or lymph node but led
to significant increases in proliferation of both subsets in blood following SIV infection. Our findings reveal that virus-
mediated activation of pDC through TLR7 and TLR9 contributes to substantial but transient IFN-a production following
pathogenic SIV infection. However, the data indicate that pDC activation and IFN-a production are unlikely to be major
factors in driving immune activation in early infection. Based on these findings therapeutic strategies aimed at blocking pDC
function and IFN-a production may not reduce HIV-associated immunopathology.
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Introduction
Chronic immune activation is a driving factor in CD4+ T cell
loss and disease progression in HIV-infected individuals, yet the
mechanisms responsible for this process are not completely under-
stood [1]. Recent comparative studies in nonhuman primate
models have shed light on the etiology of chronic immune activa-
tion [2]. Pathogenic simian immunodeficiency virus (SIV) infection
in non-natural hosts including the Asian macaque species is charac-
terized by sustained depletion of peripheral and mucosal CD4+ T
cells, microbial translocation across the gut mucosa and persistently
high levels of proinflammatory cytokines and lymphocyte activation
that culminate in disease progression and AIDS [3–7]. In contrast,
SIV infection of natural hosts such as the African green monkey and
sooty mangabey results in preserved T cell homeostasis, low levels of
chronic immune activation and a benign clinical course despite high
levels of circulating virus [8–11]. A key distinction between the two
models is that the innate immune response is rapidly resolved in
SIV-infected natural hosts, whereas upregulation of the type I inter-
feron (IFN) response and expression of IFN-stimulated genes (ISG)
persists in SIV-infected macaques [12–17]. This dichotomy suggests
that the innate immune response and persistent type I IFN produc-
tion in particular may play a key role in chronic immune activation
and disease progression [18,19].
Plasmacytoid dendritic cells (pDC) produce copious amounts of
type I IFN in response to virus exposure but their role in HIV
infection appears to be complex [20]. pDC are activated in HIV
and SIV infection and are rapidly lost from blood, coincident with
their recruitment to lymph nodes and mucosal tissues [21–27], and
within acutely infected lymph nodes IFN-a is produced largely by
pDC [16,17]. In addition, pDC may be chronically stimulated in
HIV infection and be a continuing source of IFN-a that leads to
CD4 T cell death [28–32]. These findings have led to a model in
which activated pDC that are recruited to lymphoid tissues chro-
nically produce IFN-a that drives sustained expression of ISG and
mediates T cell dysfunction and loss [18,33]. However, to date a
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direct link between the pDC response and chronic immune activa-
tion has not been made as reagents that selectively deplete pDC or
interfere with their function in nonhuman primates have not been
available. Resolving this issue has important clinical implications
as therapeutic strategies aimed at disrupting pDC function are being
considered as a means of controlling HIV-associated immunopa-
thology [34,35].
pDC are activated by HIV and SIV nucleic acids to produce
IFN-a and TNF-a through engagement of endosomal receptors
TLR7 and TLR9 [36,37], and dual antagonists comprised of
nonstimulatory DNA sequences have been developed that block
pDC stimulation through these receptors [38]. These compounds
have been used to demonstrate the critical contribution of pDC to
systemic lupus erythematosis and skin autoimmune disease in
mouse models [39,40]. In the present study, we used a dual TLR7
and TLR9 antagonist to selectively block the response of pDC but
not other mononuclear phagocytes to viral RNA in SIV-infected
rhesus macaques and directly determine the role of pDC in
immune activation.
Results
TLR7 and TLR9 antagonist has selective activity against
rhesus macaque pDC
To determine if TLR7 and TLR9 blockade was effective at selec-
tively inhibiting pDC responses to SIV in rhesus macaques, we first
tested the specificity and efficacy of a TLR7 and TLR9 antagonist
in vitro. Peripheral blood mononuclear cells (PBMC) and peripheral
lymph node cell suspensions from healthy SIV-naı¨ve macaques
were incubated with aldrithiol-2-inactivated SIVmac239 particles
(iSIV) or influenza virus in the presence or absence of DV056, a 25-
based single-stranded phosphorothioate oligodeoxynucleotide anta-
gonist of TLR7 and TLR9 that contains the necessary inhibitory
motifs with optimization for activity in nonhuman primates and
humans [37]. After incubation cytokine production was determined
by flow cytometry using standard approaches to define mononu-
clear phagocytes (Figure 1A) [23,41]. Blood and lymph node pDC
produced abundant IFN-a and TNF-a in response to iSIV and
influenza virus, which was potently blocked by DV056 (Figure 1B).
pDC were the exclusive producers of IFN-a in SIV-naive blood in
response to stimulation with iSIV, live SIV, influenza virus and the
TLR9 agonist CpG-C, as shown by the lack of IFN-a secretion from
stimulated PBMC that were depleted of pDC (Figure 1C). More-
over, DV056 completely blocked secretion of IFN-a from unsepa-
rated PBMC in response to these varied stimuli, demonstrating
the activity of the drug in antagonizing both TLR7 and TLR9
(Figure 1C). In contrast, DV056 did not impair TNF-a production
from blood and lymph node myeloid DC (mDC) and blood
monocytes or TNF-a and IFN-a production from lymph node
macrophages in response to stimulation with iSIV, consistent with
the fact that these cells recognize viral RNA through receptors other
than TLR7 and TLR9 (Figure 1D) [42].
In vivo delivery of TLR7 and TLR9 antagonist blocks
responsiveness of rhesus blood and lymph node pDC to
virus stimulation
We next determined the capacity of DV056 to block the
response to viral RNA in rhesus macaques in vivo. We treated 4
SIV-naive macaques with DV056 at a dose of 2 mg/kg by weekly
subcutaneous injections and collected PBMC 3 days after each
injection for functional analyses. This drug regimen was based on
preliminary studies showing that a similar dose and course of a
related TLR7 and TLR9 antagonist in macaques blocked the ex
vivo induction of ISG in PBMC in response to influenza virus
stimulation (F.J.B., unpublished data). After a single treatment the
proportion of blood pDC producing cytokines in response to virus
stimulation dropped by 80 to 90%. In addition, the amount of
each cytokine produced by pDC as judged by mean fluorescence
intensity was substantially reduced in DV056-treated macaques
(Figure 2A, B). To assess the level of blockade in lymphoid tissues
we harvested inguinal lymph nodes 3 days after the third dose of
DV056 to allow time for accumulation of drug in tissues. The
mean proportion of lymph node pDC producing IFN-a in DV056
treated animals dropped by 66% and 85% following stimulation
with iSIV and influenza virus, respectively, relative to untreated
lymph nodes, accompanied by marked reductions in the amount
of cytokine produced. Reductions in lymph node pDC production
of TNF-a ranged from 54% to 75% for iSIV and influenza virus,
respectively (Figure 2A, B). The responsiveness of mDC and
monocytes/macrophages in each compartment was unaffected by
DV056 treatment (data not shown).
TLR7 and TLR9 blockade does not alter virus load or pDC
kinetics following SIV infection
After a total of 4 weekly doses of DV056 we infected the 4 rhesus
macaques with SIVmac251 intravenously and continued weekly
drug dosing up to day 53 post infection, encompassing the critical
acute-to-chronic phase when immune activation is established. In
parallel we infected 5 untreated macaques with the same dose of
virus as controls. The kinetics of viremia were highly similar in both
groups of animals, with nearly identical peak virus loads at day 11
and virus set-points at around day 70 post infection (Figure 3A).
Infection was associated with a marked increase and then decline in
the number of blood pDC which then steadily returned to pre-
infection levels by around day 30 post infection, and these kinetics
were unaffected by DV056 treatment (Figure 3B). Acute infection
was also associated with a significant increase in the proportion
of pDC expressing the chemokine receptor CCR7 regardless of
DV056 treatment, consistent with the potential for blood pDC to
migrate to lymph nodes (Figure 3C).
Author Summary
A persistent type I interferon (IFN) response is thought to
be important in driving immune activation and progres-
sion to AIDS in human immunodeficiency virus (HIV)-
infected individuals. Plasmacytoid dendritic cells (pDC)
produce copious amounts of type I IFN upon virus expo-
sure through engagement of Toll-like receptor (TLR) 7 and
TLR9 and thus may be central players in the etiology of
immune activation. We used a dual antagonist of TLR7 and
TLR9 to selectively block the response of pDC but not
other mononuclear phagocytes prior to and for 8 weeks
following simian immunodeficiency virus (SIV) infection of
rhesus macaques. We show that pDC are major, but not
exclusive, producers of IFN-a that mediate a marked but
transient IFN-a response in lymph nodes in the acute
phase of infection. TLR7 and TLR9 antagonist prevented
this IFN-a production without suppressing pDC recruit-
ment. Nevertheless, TLR7 and TLR9 blockade did not
impact expression of IFN-stimulated genes or decrease the
activation of T cells, the hallmarks of immune activation.
The findings indicate that TLR7 and TLR9-driven activation
of pDC is unlikely to be a major contributor to immune
activation in the early stages of immunodeficiency virus
infections and suggest that therapeutic strategies aimed at
targeting pDC and IFN-a production may not reduce HIV-
associated immunopathology.
TLR7 and TLR9 Blockade in Early SIV Infection
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TLR7 and TLR9 antagonist blocks pDC responses in SIV-
infected macaques
We next harvested PBMC from DV056-treated and control
macaques and measured proinflammatory cytokine production
after virus exposure ex vivo. Blood pDC from macaques that did
not receive DV056 treatment had robust IFN-a and TNF-a
production when stimulated with iSIV and influenza virus at the
time of SIV infection. However, pDC from these animals rapidly
lost responsiveness to virus stimulation ex vivo, and pDC hypores-
ponsiveness persisted into chronic infection, consistent with previous
studies (Figure 4A) [43]. pDC from monkeys in the DV056-treated
group had suppressed responses to virus stimulation at the time of
SIVmac251 infection, revealing that TLR7 and TLR9 blockade
remained effective even after multiple drug administrations, and this
suppression was sustained after infection and persisted for the length
of the study (Figure 4A). In addition, expression of IRF-7, a key
IFN-a transcription factor that is induced in pDC upon HIV
stimulation [32,44], was markedly upregulated in iSIV-stimulated
blood pDC from untreated macaques at day 0 but not at day 14 post
infection, and was not upregulated in pDC from DV056-treated
macaques at either time, consistent with both virus- and drug-
induced inhibition of pDC responses (Figure 4B). In contrast to
pDC, blood mDC gained significant capacity to produce IFN-a in
acute SIV infection when stimulated with iSIV ex vivo, although the
intensity of cytokine production based on mean fluorescence inten-
sity was relatively modest and there was considerable variation between
animals (Figure 5A, B). Notably, the enhancement of mDC func-
tion was not blocked by DV056 treatment, consistent with the
inability of TLR7 and TLR9 antagonist to impact mDC responses
to viral RNA (Figure 5A, B).
IFN-a and TNF-a are differentially expressed and
impacted by TLR7 and TLR9 blockade in lymph nodes
We next determined if DV056 treatment impacted pDC recruit-
ment and cytokine production in lymph nodes following SIV infec-
tion. The frequency of CD123+ pDC within the Lineage– HLA-
DR+ fraction of cells did not change at day 14 or 56 post infection
in either DV056-treated or control animals when compared to
preinfection samples (Fig. 6A). However, the proportion of lymph
node pDC that was BrdU+ increased significantly at day 14 post
Figure 1. TLR7 and TLR9 antagonist selectively blocks proinflammatory cytokine production from uninfected rhesus macaque pDC.
(A) Representative gating strategy to define pDC, mDC, monocytes (Mo) and macrophages (Mø) by flow cytometry in rhesus macaque PBMC and
lymph node. The lymph node gate to define DC includes autofluorescent cells that encroach on the Lineage+ subset, as previously described [23]. (B)
PBMC and lymph node cell suspensions from SIV-naive animals were stimulated with iSIV or influenza virus with and without DV056 and intracellular
expression of IFN-a and TNF-a in pDC was determined by flow cytometry. Positive labeling with cytokine-specific antibody as shown by the boxed
areas was based on isotype control antibody. Numbers represent the percent positive cells. (C) PBMC, pDC-depleted PBMC and PBMC pretreated with
DV056 were stimulated with iSIV, live SIV, influenza virus or CpG-C and supernatants were analyzed for IFN-a by ELISA. Unstimulated PBMC served as
a negative control. (D) PBMC and lymph node cell suspensions were stimulated with iSIV or influenza virus and IFN-a and/or TNF-a in mDC,
monocytes or macrophages were determined by flow cytometry. SSC = side scatter.
doi:10.1371/journal.ppat.1003530.g001
TLR7 and TLR9 Blockade in Early SIV Infection
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infection in both groups, reflecting the influx of recently divided
pDC to lymph nodes [25] that occurred regardless of TLR7 and
TLR9 blockade (Fig. 6A). We next analyzed serial sections of
lymph nodes for in situ expression of IFN-a and TNF-a, quanti-
fying the frequency of cytokine-expressing cells using imaging
software (Figure S1). In lymph nodes from untreated macaques at
day 14 post infection IFN-a-expressing cells were frequent in lymph
nodes, with an average of 0.5% of all cells in the paracortex and
parafollicular cortex producing IFN-a. This expression was tran-
sient, as by day 56 post infection IFN-a-producing cells were rarely
identified and their frequencies approximated those of naive lymph
nodes (Fig. 6B,C). In contrast, animals receiving DV056 treatment
did not experience this transient increase in IFN-a production in
acute infection; IFN-a-producing cells were rare in the paracortex
and parafollicular cortex at both day 14 and 56 post infection with
frequencies similar to that seen in naive macaques (Fig. 6B,C). A
majority but not all of the IFN-a expressing cells in untreated
lymph nodes co-expressed CD123, indicating that pDC were major
but not exclusive producers of IFN-a in the absence of DV056
treatment. Additional double labeling experiments revealed IFN-a
production by CD163+ macrophages and by mDC, identified
using antibody to CD1a (Fig. 6D) [23]. IFN-a in lymph nodes from
DV056-treated macaques did not co-stain with antibody to CD123
but was largely restricted to macrophages and mDC (Fig. 6D and
data not shown). In contrast to IFN-a, massive numbers of TNF-a-
producing cells were present in lymph nodes at both day 14 and 56
post infection, regardless of TLR7 and TLR9 blockade, with 25 to
30% of all cells in the paracortex and parafollicular cortex expres-
sing this cytokine (Fig. 6B,C). TNF-a producing cells were primarily
CD163+ macrophages and CD3+ T cells (Fig. 6D). CD123+ pDC
that co-labeled with antibody to TNF-a were rarely identified, even
in the untreated animals (data not shown).
TLR7 and TLR9 blockade has minimal impact on plasma
IFN-a and expression of ISG after SIV infection
We next evaluated the impact that DV056 treatment had on the
systemic type I IFN response following infection. In macaques that
were SIV-infected without concurrent TLR7 and TLR9 blockade
we detected a robust and transient increase in plasma levels of
IFN-a which peaked at day 11 post infection. DV056-treated maca-
ques had nearly identical plasma IFN-a responses (Figure 7A). To
determine the impact that TLR7 and TLR9 blockade had on ISG
expression, we analyzed the relative expression of 6 genes (IRF-7,
Mx-b, ISG-20, 2.5 OAS, GBP-1 and ISG-54) that are induced in
blood and lymph node CD4+ T cells in SIV-infected macaques
[14,15]. In PBMC from untreated animals ISG responses paralleled
those of plasma IFN-a, peaking at day 11 post infection and then
dropping to near pre-infection levels (Figure 7B). Induction of
Figure 2. In vivo administration of TLR7 and TLR9 antagonist to rhesus macaques blocks pDC responses to virus stimulation. DV056
was administered by weekly subcutaneous injection at 2 mg/kg to SIV-naive rhesus macaques, and PBMC and lymph node cell suspensions collected
3 days after administration were stimulated with iSIV and influenza virus to assess TLR7 and TLR9 blockade. (A) pDC production of IFN-a and TNF-a in
PBMC and lymph node cell suspensions from untreated and DV056-treated macaques. Flow cytometric gating was done as in Figure 1. (B) The
percent of pDC in PBMC (left) and lymph node cell suspensions (right) from DV056-treated macaques (n = 4) compared to untreated macaques (n = 12
for PBMC, n = 8 for lymph node) producing IFN-a and TNF-a in response to iSIV and influenza virus stimulation. Each symbol represents an individual
animal and horizontal lines represent means. **P,.01.
doi:10.1371/journal.ppat.1003530.g002
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expression of all ISG examined was impacted minimally or not at all
by DV056 treatment (Figure 7B). In lymph node cell suspensions of
untreated macaques, expression of ISG increased progressively
from day 14 to day 56, in contrast to blood (Figure 7C). Treatment
with DV056 blocked the induction of IRF-7 but otherwise did not
diminish expression of ISG in lymph nodes subsequent to SIV
infection (Figure 7C).
TLR7 and TLR9 blockade does not diminish CD4+ and
CD8+ memory T cell activation and proliferation in blood
or lymph node
To determine if T cell activation and proliferation were impac-
ted by TLR7 and TLR9 blockade, we analyzed CD4+ and CD8+
T cell subsets in blood and lymph node cell suspensions in DV056-
treated and untreated macaques by flow cytometry (Figure 8A).
We focused on the memory subsets characterized by high expres-
sion of CD95 with and without expression of CD28, as dysregula-
tion is most prominent in these cells [45]. The number of CD4+ T
cells in peripheral blood rapidly and transiently declined at day 11
post infection before rebounding and then steadily declining in
untreated macaques. In macaques treated with DV056 blood CD4
T cell counts were transiently increased at day 4 and day 21 post
infection, although the pattern of changes in CD4+ T cell counts
over time was not significantly different between groups (Figure 8B).
In untreated macaques SIV infection resulted in the continual
increase in frequency of memory CD4+ and memory CD8+ T cells
in blood expressing Ki67, an indicator of recent proliferation, and
the activation marker CD38 [46]. The frequency of memory T cells
expressing CD38 was not altered in DV056 treated macaques,
while the frequency of both memory T cell subsets expressing Ki67
actually increased over time as a result of DV056 treatment (Figure 8C).
In inguinal lymph node cell suspensions the increase in proliferating
memory T cell subsets following SIV infection, as determined by
BrdU incorporation, was almost identical in control and DV056-
treated macaques (Figure 8D). The frequency of memory T cell
subsets in lymph nodes expressing the activation marker CD38
approached 90% to 100% in both groups indicating profound
activation regardless of DV056 treatment (Figure 8D).
Discussion
This study is the first to directly dissect the role of innate immu-
nity in driving immune activation in pathogenic SIV infection of
rhesus macaques, a model that produces AIDS-like disease very
similar to HIV infection in humans but with an accelerated time
frame [47]. We have demonstrated that stimulation of pDC by
viral RNA through engagement of TLR7 and TLR9 induces a
robust but transient IFN-a response in the lymph nodes of SIV-
infected rhesus macaques, and provide evidence that this response
in itself is insufficient to drive persistent ISG expression and
immune activation that distinguishes pathogenic from nonpatho-
genic models [13–15].
While pDC were found to be major producers of IFN-a in
response to SIV infection, they were not exclusive producers of this
cytokine. Macrophages from naı¨ve macaques produced IFN-a
when stimulated in vitro with iSIV and were found to contribute
to IFN-a production in lymph nodes during the acute phase of
Figure 3. TLR7 and TLR9 blockade does not impact virus load or pDC kinetics. (A) SIV RNA copies/ml of plasma for untreated (n = 5) and
DV056-treated (n = 4) macaques over time as determined by quantitative RT-PCR. Shown are virus loads for each animal in untreated and DV056-
treated groups as well as geometric means for each group. (B) Absolute counts of pDC in blood for untreated and DV056-treated macaques over
time. Shown is the percent change in cell counts relative to preinfection levels for each animal in untreated and DV056-treated groups as well as
means for each group. (C) Percent of CCR7+ pDC in blood over time. Shown is the percent pDC expressing CCR7 before and after SIV infection for
each animal in untreated and DV056-treated groups as well as the means for each group.
doi:10.1371/journal.ppat.1003530.g003
TLR7 and TLR9 Blockade in Early SIV Infection
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infection, although as shown here for pDC, macrophages and
monocytes also become refractory to stimulation following SIV
infection [43]. Conversely, while mDC from SIV naı¨ve animals
are largely incapable of producing IFN-a upon stimulation with
SIV or virus-encoded oligonucleotides [43], we found that mDC
taken after infection gained a modest capacity to produce IFN-a
upon virus stimulation and also contributed to in situ-IFN-a
production in acutely infected lymph nodes. Similarly, in humans
with chronic HIV infection, macrophages, mDC and lymphocytes
produce IFN-a in the spleen and appear to be greater overall
contributors to IFN-a production than pDC [48]. These findings
reflect the fact that multiple cell types including hematopoietic and
non-hematopoietic cells produce type I IFN through both TLR-
dependent and independent pathways, depending on the type of
stimulus [49]. Indeed, in murine models of virus infection ablation
of pDC impacts IFN-a production only in the very early stages
after infection, up to 36 hours; non-pDC are responsible for IFN-a
at later time points [50]. The redundancy in IFN-a production
may explain why blocking TLR7 and TLR9 function did not
substantially diminish the peak plasma IFN-a response or alter the
kinetics of ISG expression in infected monkeys. In addition, it is
possible that the dramatically reduced levels of IFN-a in lymph
nodes of DV056-treated animals are nevertheless sufficient to
induce the high levels of ISG observed in these tissues, or that
Figure 4. TLR7 and TLR9 antagonist blocks pDC responses following SIV infection. (A) Percent of blood pDC producing IFN-a and TNF-a
after stimulation with iSIV and influenza virus following SIVmac251 infection. Shown is the percent of cytokine-expressing pDC for each animal in
untreated (n = 5) and DV056-treated (n = 4) groups as well as means for each group. The difference between untreated and DV056-treated profiles
was statistically significant for both viruses and both cytokines (P,.01). (B) IRF-7 expression in pDC from an untreated and DV056-treated macaque at
day 0 and day 14 post infection after stimulation with iSIV (solid line) or no stimulation (dotted line) relative to isotype control antibody (filled
histogram).
doi:10.1371/journal.ppat.1003530.g004
TLR7 and TLR9 Blockade in Early SIV Infection
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other viral IFN including IFN-b and IFN-l that were not mea-
sured in this study contribute to a robust ISG response in the face
of TLR7 and TLR9 blockade [51].
Notably, IFN-a production in lymph nodes was transient despite
sustained high levels of virus and was temporally unrelated to
chronic immune activation. In other studies, deliberately increasing
levels of IFN-a in chronically infected sooty mangabeys through
exogenous injection of an IFN-a agonist does not induce lympho-
cyte activation but reduces virus load [52]. In addition, in indivi-
duals with chronic HIV infection systemic IFN-a administration
reduces virus load even as it enhances CD8+ T cell activation
[53,54]. Collectively, these data do not support a direct pathologic
role for IFN-a in disease progression in HIV infection. It is possible
that chronic immune activation that is the hallmark of pathogenic
SIV and HIV infection is more a consequence of sustained exposure
to microbial products that have been translocated across the gut
lumen, resulting in persistent activation of mononuclear phagocytes
and other cells through the actions of lipopolysaccharide [7,55].
TNF-a overproduction by a subset of blood monocytes in response
to microbial products has been demonstrated in HIV viremic indi-
viduals, providing a mechanistic link between microbial transloca-
tion and systemic inflammation [56]. In our study copious in situ
TNF-a production was temporally associated with ISG expression
in lymph nodes, and other cytokines including TGF-b, IL-1b and
IL-15 that are increased in lymph nodes in acute SIV and HIV
infection may also play a role either directly or indirectly in immune
activation and disease progression [57–59].
We were unable to sample gut mucosal tissues for pDC activity
and TLR7 and TLR9 blockade and therefore cannot rule out the
possibility that pDC recruited to these tissues maintained contin-
uous production of IFN-a that drove ISG expression and immune
activation [26,27]. Phosphorothioate oligonucleotides have very
predictable pharmacokinetics across species, with rapid clearance
from plasma and accumulation primarily in lymphoid tissues, liver
and kidney with a half-life of 2–6 days [60–63], and studies with a
related TLR7 and TLR9 antagonist to DV056 indicate a similar
profile (C.G. and F.J.B., unpublished data). These compounds also
accumulate in intestine at levels 3–6 times that of blood [61,64]. We
would therefore predict that DV056 blocked pDC responses in
mucosal tissues as it did in lymphoid tissues. Evidence also suggests
that mucosal pDC become hyporesponsive to stimulation and IFN-
a production subsequent to SIV infection [27], as they do in lym-
phoid tissues [43]. Further studies are needed to directly investigate
the response of pDC and other mononuclear phagocytes in mucosal
tissues and its relationship to disease progression.
TLR7 and TLR9 antagonist did not suppress the upregulation
of CCR7 by pDC or their recruitment to lymph nodes in acutely
infected macaques, despite the fact that HIV-mediated activation
of TLR7 drives CCR7 upregulation in these cells [65]. This could
be explained by the fact that the viral matrix protein alone induces
functional CCR7 expression on pDC without inducing IFN-a
[66], and this pathway would be intact in our study animals as
TLR7 and TLR9 blockade did not reduce the amount of circu-
lating virus. These findings reinforce those in the mouse model of
autoimmune skin disease [40] and highlight the fact that pDC
recruitment to inflamed tissues is not linked to their capacity to
secrete proinflammatory cytokines.
An unexpected finding of our study was the significant increase
in DV056-treated macaques of proliferating memory CD4+ and
CD8+ T cells in blood. These increases were not associated with
increased in virus load (data not shown) which is known to impact
T cell proliferation [67,68] and may therefore be a consequence of
TLR7 and TLR9 blockade itself. The mechanism for this enhanced
proliferative response and its biologic relevance is unclear at present.
TLR-mediated activation of DC is known to impact regulatory T
cell development and influence CD4+ T cell proliferation [69,70],
but the impact of selectively blocking TLR7 and TLR9 on T cell
proliferation in the context of SIV or HIV infection has not been
studied and deserves further attention.
Our findings support the conclusion that TLR7- and TLR9-
mediated activation of pDC leads to significant and transient IFN-
a production in lymph nodes but may not by itself drive the
pathologic process of immune activation. The data reinforce the
findings of others [16,17] showing that production of IFN-a from
activated pDC that have been recruited to lymph nodes in early
infection does not define pathogenic SIV infection, contrary to
earlier findings [37]. Our findings suggest that specifically target-
ing pDC as a therapeutic strategy to reduce immunopathology in
HIV infection may have limited benefit [34], at least in the early
stages of infection. It will be important to determine whether
TLR7- and TLR9-driven activation of pDC plays any role in
Figure 5. mDC gain the capacity to secrete IFN-a upon virus
stimulation following SIV infection. (A) Dot plots showing
intracellular IFN-a expression in blood mDC from untreated and
DV056-treated macaques at day 0 and day 14 post infection after iSIV
stimulation. Data for all animals are shown, along with a representative
dot plot of cells exposed to control microvesicles. Flow cytometric
gating to define mDC was done as in Figure 1. (B) Percent of blood
mDC producing IFN-a after iSIV stimulation at the indicated times after
infection in untreated and DV056-treated macaques. *P,.05, **P,.01.
doi:10.1371/journal.ppat.1003530.g005
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immune activation in the chronic stages of infection when disease
is manifest.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. All animal proce-
dures were performed according to a protocol approved by the
Institutional Animal Care and Use Committee of the University of
Pittsburgh (protocol number: 1002392). Appropriate sedatives,
anesthetics and analgesics were used during handling and surgical
manipulations to ensure minimal pain, suffering and distress to
animals.
Animals, treatments and sample collection
Nine Indian-origin rhesus macaques (Macaca mulatta) were used
in the study. Four macaques were treated with the dual TLR7 and
TLR9 antagonist DV056 (Dynavax Technologies), by weekly
subcutaneous injections at 2 mg/kg, with 4 doses prior to and 8
doses after SIV infection. All macaques were infected by intra-
venous inoculation with 300 TCID50 SIVmac251 (provided by
Preston Marx, Tulane National Primate Research Center).
Bromodeoxyuridine (BrdU; Sigma) was administered by intrave-
nous injection at 30 mg/kg at 24-h intervals for 3 days prior to
collection of peripheral lymph nodes at day 27, 14 and 56 post
infection, which were processed as previously described [23]. The
quantitative real-time RT-PCR assay to determine SIV viral load
was performed as previously described [25].
Flow cytometry
The following monoclonal antibodies were used to label PBMC
and lymph node cell suspensions and were purchased from BD
Biosciences unless otherwise noted: CD3 (clone SP34-2), CD20
(eBiosciences, 2H7), CD14 (MøP9), CD123 (7G3), CD11c (S-
HCL-3), HLA-DR (L243 or G46-6), CD163 (GHI/61), CCR7
(150503, R&D Systems), CD4 (L200), CD8 (RPA-T8), CD28
(CD28.2), CD38 (AT-1, Stem cell Technologies), CD95 (DX2),
IRF-7 (H-246, Santa Cruz Biotechnology) and Ki67 (B56). Flow
cytometric analysis and determination of blood pDC and CD4+ T
cell counts were done as described [25,41]. For detection of
intracellular cytokines, cells were first labeled with surface-binding
antibody and then fixed and permeabilized prior to incubation
with antibody to TNF-a (MAb11) and IFN-a (225.C). In vivo
incorporation of BrdU was detected using a BrdU-FITC staining
kit (BD Biosciences). Dead cells were excluded using a Live/Dead
viability kit (Invitrogen). Cells were run on a BD LSR-II flow
cytometer system, collected with BD FACS Diva 6.0 software, and
analyzed with FlowJo 8.8.7 (TreeStar). In general 1 million live
cells were analyzed resulting in between 600 and 2,000 events of
the respective mononuclear phagocyte subset after gating.
Cell stimulations and pDC depletion
PBMC and lymph node cell suspensions were stimulated at
2.56106 cells/well for 7 h with iSIV at a capsid concentration of
200 ng/ml, virus-free microvesicles at 200 ng/ml, live SIVmac239
at a capsid concentration of 400 ng/ml (SIV preparations provided
by Jeffrey D. Lifson, AIDS and Cancer Virus Program, SAIC-
Frederick), live H7N3 influenza virus (provided by Ted M. Ross,
University of Pittsburgh) at a multiplicity of infection of 5, or CpG-
C oligodeoxyribonucleotide C274 (Integrated DNA Technologies)
at a concentration of 5 ug/ml with and without prior incubation of
cells with 1 mM DV056 for 1 h. Data generated using microvesicles
as controls showed background cytokine production similar to
unstimulated cells stained with isotype control antibody. In some
experiments pDC were depleted from PBMC by labeling cells with
PE-conjugated antibody to CD123 followed by anti-PE microbeads
(Miltenyi) and then passing cells through a magnetic column (Miltenyi).
For flow cytometric analysis, cytokine secretion was blocked by
addition of 5 mg/ml brefeldin-A (BD Biosciences) after 2 h.
Determination of secreted IFN-a
IFN-a in plasma and culture supernatants was measured using a
commercial ELISA (multi-subtype IFN-a ELISA kit, PBL Biome-
dical) according to the manufacturer’s instructions.
Immunofluorescence of lymph node sections
Lymph nodes were prepared as described [23], cut to 7 mm –
thick sections and stained overnight with mAb to IFN-a (MMHA2,
PBL Interferon Source), TNF-a or isotype-matched antibody (BD
Bioscience). Staining was developed using goat anti-mouse-HRP
AlexaFluor 546 with tyramide signal amplification (Invitrogen). Sec-
tions were co-stained with rabbit antibody to CD3 (Dako) or bio-
tinylated mouse antibody to CD123, CD163, CD1a (SK9, BioLegend),
or isotype controls followed by donkey anti-rabbit Alexa488 secon-
dary antibody or mouse HRP-streptavidin AlexaFluor 488. Nuclei
were stained with Hoechst dye. Sections were visualized on an
Olympus Fluoview 1000 confocal microscope and analyzed using
Olympus FluoView Software. To quantify cytokine-expressing cells
at least 10 non-overlapping regions were randomly imaged and
cytokine-producing cells enumerated using image analysis software
(Figure S1). Composite images were made by scanning entire
lymph node sections using a Nikon 90i motorized epifluorescence
microscope followed by digital reassembly using NIS-Elements.
Gene expression analysis
Gene expression analysis was done as previously described [40].
Briefly, total RNA was extracted from previously cryopreserved
PBMC and lymph node cells using an RNA micro kit (QIAGEN)
and cDNA was generated with SuperScript First-Strand Synthesis
System (Invitrogen). Quantification of ISG transcripts was perfor-
med by real-time RT-PCR in triplicate using TaqMan gene
expression assays (Applied Biosystems). RCT threshold cycle (CT)
values for each gene were normalized to the housekeeping gene
Figure 6. TLR7 and TLR9 antagonist blocks transient IFN-a production by pDC in lymph nodes without suppressing recruitment. (A)
Percent of pDC in lymph nodes (left) and percent of pDC labeling with antibody to BrdU (right) in untreated (n = 5) and DV056-treated (n = 4)
macaques. Horizontal lines represent means. **P,.01. (B) Immunofluorescence of lymph node sections taken from naive and SIV-infected macaques
with and without DV056 treatment at days 14 and 56 post infection stained with antibody to IFN-a or TNF-a (red) and co-stained with Hoescht dye
(blue) to identify nuclei. Insets in naı¨ve tissue sections represent immunofluorescence after labeling with isotype control antibody. Insets in SIV-
infected sections show higher magnification images to highlight details of individual cells. Original magnification 4006. (C) Frequency of IFN-a and
TNF-a producing cells in paracortex and parafollicular cortex from naive macaques (n = 2) and macaques at day 14 and 56 post infection with (n = 4
for IFN-a, n = 3 for TNF-a) and without (n = 5 for IFN-a, n = 3 for TNF-a) DV056 treatment. **P,.01. (D) Immunofluorescence of lymph nodes from
untreated and DV056-treated macaques at day 14 post infection stained with antibody against CD123, CD1a or CD163 (green) and IFN-a or TNF-a
(red) and co-stained with Hoescht dye (blue). Arrowheads indicate cells co-labeling with cytokine- and cell-specific markers. Original magnification
4006.
doi:10.1371/journal.ppat.1003530.g006
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ubiquitin using the formula gene expression = 1.8 (Avg CT Ubi –
CT Gene)6100,000, where Ubi is the mean CT of triplicate house-
keeping gene runs, Gene is the mean CT of duplicate runs of the
gene of interest, and 100,000 is an arbitrary factor to raise values
above 1. Primer sequences used were as follows: IRF7, CTGTTTC-
CGCGTGCCCT (forward), GCCACAGCCCAGGCCTT (reverse);
Mx-b, GAGACATCGGACTGCAGAT (forward), GTGGTGG-
CAATGTCCACGTTA (reverse); 2.5 OAS, AGGGAGCATGA-
AAACACATTTCA (forward), TTGCTGGTAGTTTATGAC-
TAATTCCAAG (reverse); GBP-1, TGGAACGTGTGAAAGC-
Figure 7. Minimal impact of TLR7 and TLR9 blockade on plasma IFN-a and ISG expression. (A) Plasma IFN-a levels were quantified by
ELISA. Shown is the plasma concentration of IFN-a for each animal in untreated (n = 5) and DV056-treated (n = 4) groups as well as the means for each
group. (B) Relative expression of ISG in PBMC. Shown is the expression of the indicated genes normalized to ubiquitin for each animal in untreated
and DV056-treated groups as well as the means for each group over time. P values in A and B reflect differences between untreated and DV056
treated profiles. (C) Expression of the same genes in lymph nodes. Shown is the mean +/2 SEM for individual genes in lymph node cell suspensions
for untreated (n = 5) and DV056-treated (n = 4) macaques. P values reflect trends in gene expression over the 3 time points.
doi:10.1371/journal.ppat.1003530.g007
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TGAGTCT (forward), CATCTGCTCATTCTTTCTTTGCA
(reverse); and ISG-54, CTGGACTGGCAATAGCAAGCT (for-
ward), AGAGGGTCAATGGCGTTCTG (reverse). Primers and
probes for ISG20 (Hs00158122_m1) were provided by Applied
Biosystems.
Statistical analysis
Comparisons between treatment groups at a single time were
performed by two- or three-way ANOVA. Profiles of measure-
ments on animals assessed at multiple times were compared using
mixed effects ANOVA, with a random effect for animal and fixed
Figure 8. TLR7 and TLR9 blockade does not diminish immune activation in SIV-infected rhesus macaques. (A) Representative gating
strategy to define CD4+ and CD8+ T cell subsets in rhesus macaque PBMC. (B) Absolute counts of CD4+ T cells in blood of untreated (n = 5) and
DV056-treated (n = 4) macaques over time. Shown is the percent change in cell counts relative to preinfection levels for each animal in untreated and
treated groups as well as the means for each group. (C) Percent of CD4+ and CD8+ memory T cells in blood expressing Ki67 and CD38. Shown is the
percent expression for each animal in untreated and treated groups as well as means for each group. P values in B and C reflect differences between
untreated and DV056 treated profiles. (D) Percent of CD4+ and CD8+memory T cells in lymph nodes expressing Ki67 and CD38. Shown are mean +/2
SEM for all animals in each group. P values reflect trends in the frequency of cells over the 3 time points.
doi:10.1371/journal.ppat.1003530.g008
TLR7 and TLR9 Blockade in Early SIV Infection
PLOS Pathogens | www.plospathogens.org 11 July 2013 | Volume 9 | Issue 7 | e1003530
effects for time and other control variables. Where appropriate,
tests were performed against baseline (Day 0 or 27) within treat-
ment. For analysis of T cell subsets trend was tested by treating
time as a discrete variable [71]. Tests of profiles across treatments
were required to be significant before comparisons between treat-
ments were made at and single time. All statistical analyses were
performed using SAS v9.3 (SAS Institute).
Supporting Information
Figure S1 Quantification of cytokine-producing cells in
lymph node sections. Shown are representative images of IFN-
a and TNF-a staining of untreated animals at day 14 and day 56
post infection, respectively. Portions of actual images are shown to
highlight detail. To count nuclei, the fluorescence image of Hoescht-
labeling in the original confocal image (left) are converted to 16 bit,
gray scale images using the MetaMorph image analysis program
(Molecular Devices). Parameters for nuclear width minimum and
maximum and intensity of staining relative to background are then
set using this program. An image is generated producing a gray
scale dot over each nucleus (middle) and the corresponding nuclear
count is determined. To count cytokine+ cells, the red/green/blue
images of interest are opened in the ImageJ program (National
Institutes of Health), and all images are adjusted for brightness and
contrast. The cell counting application is launched and the image to
be counted is initialized. Cytoplasmic staining that is associated
with and surrounds at least 50% of a nucleus is identified and
marked manually with a cursor creating a dot over the respective
cell (right) and adding to a cumulative total of counted cells. The
frequency of cytokine+ cells per 10,000 cells is then calculated using
the formula: (Total number of cytokine+ cells 610,000)/total
number of nuclei.
(TIF)
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